Berlin molecular biology reagent company contributing nucleic acid isolation expertise to clinical diagnostics and extracellular vesicle research consortia.
AJ INNUSCREEN GmbH is a Berlin-based private life sciences company specializing in molecular biology reagents and nucleic acid isolation technologies, operating as part of the Analytik Jena analytical technology group. They bring commercially reproducible laboratory tools — extraction kits, purification reagents — into research consortia, providing the industrial infrastructure that enables downstream biological analysis. Their H2020 participation spans infectious disease diagnostics (Ebola rapid detection) and extracellular vesicle biology, both fields where reliable nucleic acid isolation is a critical bottleneck. They function as a commercial bridge between academic research and clinical or industrial application, supplying expertise that most university partners cannot replicate.
Contributed to both EbolaMoDRAD (rapid Ebola virus detection) and TRAIN-EV (extracellular vesicle research), projects where nucleic acid extraction and purification are central technical requirements.
Participated in EbolaMoDRAD under IMI2-RIA funding, an industry-academia consortium developing bedside diagnostics for Ebola virus — their largest H2020 award at EUR 175,000.
Member of TRAIN-EV, a Marie Curie Innovative Training Network covering exosomes, EVs, cancer biomarkers, autoimmunity, and drug delivery applications.
TRAIN-EV keywords explicitly include 'industry', 'clinical', and 'academia', confirming INNUSCREEN's role as the commercial partner bridging bench research and real-world application.
In their first H2020 project (2015–2018), INNUSCREEN focused on acute infectious disease response, contributing molecular diagnostic tools to the Ebola bedside detection effort under the IMI2 framework — an applied, clinical-urgency context. Their subsequent participation in TRAIN-EV (2017–2022) marked a clear pivot toward chronic disease and oncology, with keywords concentrated on extracellular vesicles, cancer biomarkers, autoimmunity, and therapeutic targets. This shift from emergency infectious disease diagnostics toward EV-based liquid biopsy research reflects the broader industry move from acute pathogen detection toward precision medicine and non-invasive disease monitoring.
INNUSCREEN is moving from acute infectious disease diagnostics toward extracellular vesicle-based biomarker research, positioning them as a natural industrial partner for future consortia in liquid biopsy, cancer diagnostics, and EV-based drug delivery.
INNUSCREEN has never led an H2020 project — all participation is as a consortium member, indicating they prefer or are positioned as specialist contributors rather than research coordinators. Their 26 unique partners across 14 countries from just 2 projects reflects the large, structured consortia typical of IMI2 and MSCA-ITN programmes, where industrial partners are recruited for defined technical capabilities. Expect them to deliver specific laboratory tools or industrial expertise rather than drive research strategy or project management.
With 26 unique consortium partners across 14 countries from only 2 projects, INNUSCREEN has connected into genuinely broad European networks — a direct consequence of the large, multi-institutional consortia required by IMI2 and MSCA-ITN funding schemes. Their network is wide but shallow, built through programme structure rather than repeated bilateral partnerships.
INNUSCREEN occupies a specific niche that most academic partners cannot fill: a commercial supplier of reproducible, quality-controlled molecular biology reagents with demonstrated experience in both clinical-urgency (Ebola) and frontier-research (EV biology) consortia. For consortium builders who need an industrial partner to validate research tools against real-world application standards, INNUSCREEN provides both the product credibility and the Analytik Jena group's broader analytical instrumentation ecosystem. They are more valuable than a generic reagent distributor because they come with IMI2 and MSCA consortium track records.
